

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to head and neck cancer prescribing.

Question:

1. Does your Trust treat patients for head and neck cancer (Squamous cell carcinoma)? If no, which Trust do you refer patients onto for treatment?

Answer:

Yes.

Question:

2. Within your trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following?
 - Surgery only
 - Radiotherapy only
 - Surgery + Radiotherapy
 - Carboplatin (only or in combination with 5-FU)
 - Cisplatin (only or in combination with 5-FU)
 - Cetuximab with/without chemotherapy
 - Cetuximab with radiotherapy
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Docetaxel (only or in combination with 5-FU)
 - Fluorouracil (5FU) monotherapy
 - Any other chemotherapy (without radiotherapy)
 - Any other chemotherapy (with radiotherapy)
3. Could you please provide the number of patients treated in the past 3 months with the following agents for metastatic head and neck cancer (squamous cell carcinoma)?

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
*Lothian NHS Board is the common
name of Lothian Health Board*



- Cetuximab with/without chemotherapy
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Nivolumab
- Docetaxel (only or in combination with 5-FU)
- Any other chemotherapy (without radiotherapy)
- Any other chemotherapy (with radiotherapy)

4. How many patients who received Pembrolizumab for head and neck cancer (squamous cell carcinoma) in the last 3 months, received:

- Treatment every 3 weeks (200mg, Q3W)
- Treatment every 6 weeks (400mg, Q6W)

Answer:

I am advised that we would be unable to answer questions 2 to 4 for the specific histology requested (Squamous Cell Carcinoma) as the clinical systems we extract the treatment data from do not record the diagnosis to the required level of detail. We would also be unable to provide surgery-only numbers for question 2 and would not be unable to provide specific breakdowns for metastatic patients in question 3.

We could provide overall numbers for Head & Neck receiving SACT and/or Radiotherapy in the last 3 months if this assist with your request – please let us know?

Question:

5. Does your trust participate in any clinical trials for head and neck cancer? If so, please provide the trial details and number of patients who are taking part.

Answer:

| Full Title | Recruited |
|--|-----------|
| JADE, A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | 5< |

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request. I am sorry I cannot help with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive